We hope to inspire you at the 2026 AACR Annual Meeting in San Diego, where 7 cutting-edge scientific posters from PamGene and our collaborators will highlight how our functional kinase activity profiling technology provides new insights into kinase signaling and networks that drive cancer progression, drug response, and therapeutic resistance across multiple cancer types. These studies showcase the broad applicability of our KinomePro platform in Oncology and Precision Medicine, from biomarker discovery to evaluating novel therapeutic candidates.
Visit us at Booth # 2458.
Poster Highlights:
- Network Validation of Kinase Predictions in B-cell Lymphoma
Introduces a novel network-based approach linking kinase activity to drug target proximity, demonstrating how biologically relevant kinase predictions can be validated and optimized for drug discovery. - Network-Level Determinants of Drug Sensitivity in B-cell Lymphoma
Shows that drug response is governed by signaling network architecture rather than single kinases, identifying distinct pathway clusters (e.g. PI3K/AKT/mTOR vs. cell cycle pathways) associated with therapeutic sensitivity. - B-cell Receptor-Targeting Antibodies Induce Broad Kinase Inhibition
Demonstrates that monoclonal antibodies targeting the B-cell receptor complex trigger widespread kinase inhibition and apoptosis, supporting their potential as novel therapies for leukemia and lymphoma. - Kinome Profiling of PROTAC-Based Strategies in Triple-Negative Breast Cancer
Reveals that targeted protein degraders selectively disrupt key kinase pathways, reducing proliferation and inducing apoptosis in aggressive breast cancer models. - Kinase Signaling Shifts in Therapy-Resistant Pediatric Cancer Models
Identifies adaptive kinase pathway changes in ALK inhibitor-resistant rhabdomyosarcoma, uncovering potential vulnerabilities in PI3K/AKT and CDK signaling for combination therapies. - Targeting Cancer Stem Cells via Tyrosine Kinase Modulation
Highlights a novel glycosaminoglycan mimetic approach that selectively targets tyrosine kinase receptors in colorectal cancer stem cells, offering a promising therapeutic strategy. - Kinome Adaptations to Tumor Treating Fields in Glioblastoma
Shows that Tumor Treating Fields induce distinct kinase activity changes in resistant glioblastoma, revealing new opportunities for combination treatments with targeted kinase inhibitors.
Across all 7 presentations, a consistent theme emerges: cancer drug response is governed by complex, interconnected signaling pathways. By enabling high-resolution analysis of kinase activity, PamGene’s platforms help researchers uncover these network dependencies and identify new opportunities for targeted and combination therapies. PamGene’s presence at AACR 2026 underscores our continued commitment to advancing functional proteomics and supporting the development of more effective, personalized cancer treatments.
View all abstracts here: AACR 2026 Abstracts
